Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

NAFLD in 2014

Genetics, diagnostics and therapeutic advances in NAFLD

Nature Reviews Gastroenterology & Hepatology volume 12, pages 65–66 (2015)Cite this article

Subjects

In 2014, NAFLD was confirmed as the fastest growing aetiology for hepatocellular cancer in the USA. However, 2014 also saw progress in our understanding of the heritability and pathogenesis of NAFLD, and an important clinical trial targeting the farnesoid X receptor pathway has illustrated advances in developing a pharmacological therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Potential effects of obeticholic acid on NASH.

References

  1. Neuschwander-Tetri, B. A. et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52, 913–924 (2010).

    Article  CAS  Google Scholar 

  2. Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686–690 (2013).

    Article  CAS  Google Scholar 

  3. Dunn, W. et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am. J. Gastroenterol. 103, 2263–2271 (2008).

    Article  Google Scholar 

  4. Siddiqui, M. S. et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis associate with atherogenic lipoprotein profile. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2014.10.008.

  5. Rosenson, R. S., Otvos, J. D. & Freedman, D. S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90, 89–94 (2002).

    Article  CAS  Google Scholar 

  6. Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352–356 (2014).

    Article  CAS  Google Scholar 

  7. Mittal, S. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma: consider the population. J. Clin. Gastroenterol. 47 (Suppl.), S2–S6 (2013).

    Article  Google Scholar 

  8. Wong, R. J., Cheung, R. & Ahmed, A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59, 2188–2195 (2014).

    Article  Google Scholar 

  9. Bastati, N. et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271, 739–747 (2014).

    Article  Google Scholar 

  10. Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(14)61933-4.

Download references

Acknowledgements

This work of the authors is supported in part by a grant from the NIH T32 DK 07150 and RO1 DK 81410 to A.J.S.

Author information

Authors and Affiliations

  1. Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Arkes Pavillion, 14-005, Chicago, 60527, IL, USA

    Mary E. Rinella

  2. VCU School of Medicine, Virginia Commonwealth University, Box 980341, Richmond, 23298-0341, VA, USA

    Arun J. Sanyal

Authors
  1. Mary E. Rinella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arun J. Sanyal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arun J. Sanyal.

Ethics declarations

Competing interests

M.E.R. has served as a consultant to AbbVie, Fibrogen, Genentech, NGM Biopharmaceuticals and Takeda, W.L. Gore and Associates. A.J.S. has stock options in Genfit. He has served as a consultant to AbbVie, Astra Zeneca, Exhalenz, Fibrogen, Genfit, Immuron, Nimbus, Nitto Denko, Salix, Takeda and Tobira. He has been an unpaid consultant to Intercept and Echosens. His institution has received grant support from Gilead, Novartis, Salix, and Tobira.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rinella, M., Sanyal, A. Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol 12, 65–66 (2015). https://doi.org/10.1038/nrgastro.2014.232

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.232

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing